Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS
Healthcare Corporation (VITAS), the nation�s largest provider of
end-of-life care, and Roto-Rooter, the nation�s largest commercial
and residential plumbing and drain cleaning services provider,
reported financial results for its first quarter ended March 31,
2009, versus the comparable prior-year period, as follows:
Consolidated operating results from continuing operations:
- Revenue increased 3.4% to $294.9
million
- Diluted EPS increased 30.8% to
$0.85
- Adjusted Diluted EPS increased
28.8% to $0.94
VITAS segment operating results:
- Net Patient Revenue of $208.4
million, up 5.0%
- Average Daily Census (ADC) of
11,728, up 0.3%
- Average Length of Stay in the
quarter of 76.6 days
- Net Income of $17.3 million, an
increase of 30.0%
- Adjusted EBITDA of $31.2
million, an increase of 32.2%
- Adjusted EBITDA margin of 15.0%,
an increase of 308 basis points
Roto-Rooter segment operating results:
- Revenue of $86.5 million,
essentially equal to the comparable prior-year period
- Job count of 182,716, a decline
of 6.9%
- Net Income of $8.3 million, a
decline of 9.0%
- Adjusted EBITDA of $14.5
million, a decline of 9.2%
- Adjusted EBITDA margin of 16.7%,
a decline of 167 basis points
VITAS
Congress approved The American Recovery and Reinvestment Act in
late February 2009. This Act provides for an increase in the
Medicare hospice wage index for the period October 1, 2008, through
September 30, 2009. Given the timing of the passage of this Act,
VITAS did not include any adjustment to fourth-quarter 2008 revenue
for this increase in Medicare hospice reimbursement. Accordingly,
the revenue recorded in first quarter of 2009 includes
approximately $2.0 million of additional revenue that relates to
the fourth quarter of 2008.
Net revenue for VITAS was $208.4 million in the first quarter of
2009, which is an increase of 5.0% over the prior-year period.
Excluding the fourth-quarter pricing adjustment recorded in the
first quarter of 2009, revenue increased 4.0%. This revenue growth
was the result of increased ADC of 0.3% and a Medicare price
increase of approximately 3.5%. The remaining difference is
attributed to revenue and patient geographic mix.
Average revenue per patient per day in the quarter was $195.87,
which is 4.9% above the prior-year period. Routine home care
reimbursement and high acuity care averaged $152.16 and $671.03,
respectively, per patient per day in the first quarter of 2009.
During the quarter, high acuity days-of-care were 8.4% of total
days-of-care.
VITAS has recorded $270,000 of Medicare Cap liability in the
first quarter of 2009. This Medicare Cap liability relates to one
provider number that has a gross margin in excess of 20%, including
this cap liability. Admissions in this provider number increased
10% on a sequential basis.
Of VITAS� 34 unique Medicare provider numbers, 32 provider
numbers, or 94%, have a Medicare Cap cushion greater than 15% for
the current Medicare Cap year, one provider number has a 5% to 10%
cushion and one provider number has a cap liability. VITAS
generated an aggregate cap cushion of $220 million during calendar
year 2008.
The first quarter of 2009 gross margin, excluding the impact of
cap and the retro-active pricing adjustment that related to the
fourth quarter of 2008, was 22.8%. This is 276 basis points above
VITAS' gross margin in the first quarter of 2008. This is the
fourth consecutive quarter of margin increase and is a direct
result of refinements to scheduled field labor.
Selling, general and administrative expense was $17.5 million in
the first quarter of 2009, which is an increase of 8.7% when
compared to the prior year. Adjusted EBITDA totaled $31.2 million.
Excluding Medicare Cap and the impact of the fourth-quarter 2008
pricing adjustment, Adjusted EBITDA increased 25.1% over the prior
year and Adjusted EBITDA Margin increased 239 basis points to
14.3%.
Roto-Rooter
Roto-Rooter�s plumbing and drain cleaning business generated
sales of $86.5 million for the first quarter of 2009, essentially
equal to the comparable prior-year quarter. Adjusted EBITDA in the
first quarter of 2009 totaled $14.5 million, a decrease of 9.2%
from the first quarter of 2008, and equated to an Adjusted EBITDA
Margin of 16.7%.
Job count in the first quarter of 2009 declined 6.9% when
compared to the prior-year period. Total residential jobs declined
5.2%, as residential plumbing jobs decreased 4.4% and residential
drain cleaning jobs declined 5.6%, when compared to the first
quarter of 2008. Residential jobs represent approximately 70% of
total job count. Total commercial jobs declined 10.8% with
commercial plumbing job count declining 12.7% and commercial drain
cleaning decreasing 11.3%, when compared to the prior-year quarter.
These declines were partially offset by an 18.8% increase in jobs
in the �Other� category.
This job count decline was significantly mitigated relative to
total revenue through a combination of increased pricing, favorable
job mix shift to more expensive jobs such as excavation, and
increased conversion rates of calls to paid jobs.
There continues to be substantial disparity in demand for
Roto-Rooter services within the United States, although this
disparity has lessened somewhat over the past several quarters. The
South Region has experienced a 19.4% year-to-date decline in
commercial jobs while commercial volume declined 11.2% in the
Northeast Region. Residential demand is not as disparate, with the
South Region residential job count declining 11.5% while the
remaining regions have experienced a job count decline ranging from
4.5% to 9.6%.
Management continues to have discussions with existing
franchisees to acquire Roto-Rooter franchise territories. This
increase in activity is attributed to the current state of the
capital markets, the potential increase in tax rates and the
recessionary difficulties our franchisees are experiencing.
Management will continue to be highly disciplined in terms of
valuation, risk assessment and overall return on investment of any
potential acquisition. However, the timing or actual completion of
any acquisition cannot be predicted.
Chemed
Consolidated Debt and Cash Flows
Effective January 1, 2009, the Company retrospectively adopted
the provisions of FASB Staff Position No. APB 14-1, �Accounting for
Convertible Debt Instruments that May Be Settled in Cash upon
Conversion (Including Partial Cash Settlement).� This new rule
required the Company to separately account for the debt and equity
portions of its 1.875% Senior Convertible Notes (Notes). This
accounting assumed the Company could have borrowed under a
conventional seven year fixed rate interest only note at 6.875%.
The difference between the 1.875% coupon rate of the Notes and this
estimated borrowing rate created a discount on the Notes that is
recorded in equity at the inception of the debt. The Notes, net of
this discount, will be accreted to their face value over the life
of the Notes using the effective interest method. The impact of
this accounting change for the year ended December 31, 2009, is
projected to be a non-cash increase in pretax interest expense of
approximately $6.3 million ($4.0 million after-tax).
Chemed had total debt of $159 million at March 31, 2009. This
debt is net of the discount taken as a result of FASB Staff
Position No. APB 14-1. Excluding this discount, aggregate debt is
$199 million of which $187 million carries a fixed interest rate of
1.875% and is due in May 2014. The remaining debt consists of a
$12.0 million bank term loan with a current interest rate of
approximately 1.4%. Chemed�s total debt is less than one times
trailing four quarters of Adjusted EBITDA.
Chemed�s $175 million revolving credit facility expires in May
2012. At March 31, 2009, this credit facility had approximately
$149 million of undrawn borrowing capacity after deducting $26
million of letters of credit issued under this facility to secure
the Company�s workers� compensation insurance.
Net cash provided from operations in the first three months
aggregated $25.1 million. Capital expenditures for the first
quarter of 2009 aggregated $3.4 million and compares favorably to
first-quarter 2009 depreciation and amortization of $6.9
million.
Guidance for 2009
Congress has recently approved The American Recovery and
Reinvestment Act of 2009. This Act provides for an increase in the
Medicare hospice wage index for the period October 1, 2008, through
September 30, 2009. This 2009 guidance includes approximately $8.0
million in additional revenue related to this adjustment in the
Medicare hospice reimbursement rate.
VITAS expects to achieve full-year 2009 revenue growth, prior to
Medicare Cap, of 5.5% to 7.0%. Admissions are estimated to increase
1.5% to 3.5% and full-year Adjusted EBITDA Margin, prior to
Medicare Cap, is estimated to be 15.5% to 16.5%. This guidance
assumes VITAS will receive a Medicare basket price increase, net of
the BNAF phase-out, of 1.5% effective October 1, 2009. Full
calendar year 2009 Medicare contractual billing limitations are
estimated at $4.0 million.
Roto-Rooter expects to achieve full-year 2009 revenue growth of
3.0% to 4.0%. The revenue growth is a result of increased pricing
of 5.0%, a favorable mix shift to higher revenue jobs, partially
offset by a job count decline estimated at 7.0% to 9.0% Adjusted
EBITDA Margin for 2009 is estimated in the range of 17.5% to 18.5%.
This guidance does not include any Roto-Rooter franchise
acquisitions that may be completed in 2009.
Chemed�s effective tax rate has been impacted by the severe
volatility in the stock market as it relates to certain deferred
compensation investments and required generally accepted accounting
principles (GAAP) tax accounting. This stock market volatility does
not have any material impact on Chemed�s reported pretax earnings.
Excluding the impact of taxes associated with this deferred
compensation issue, Chemed�s effective tax rate for full-year 2009,
is estimated at 39.0%.
Based upon these factors and a full-year average diluted share
count of 22.6 million shares, management estimates 2009 earnings
per diluted share from continuing operations, excluding noncash
expenses for stock options, the non-cash increase in interest
expense related to the accounting change for convertible debt
interest expense and the tax rate impact from deferred compensation
investments will be in the range of $3.70 to $3.95.
Conference Call
Chemed will host a conference call and webcast at 10 a.m., EDT,
on Wednesday, April 22, 2009, to discuss the company's quarterly
results and to provide an update on its business. The dial-in
number for the conference call is (800) 320-2978 for U.S. and
Canadian participants and (617) 614-4923 for international
participants. The participant passcode is 63314619. A live webcast
of the call can be accessed on Chemed's website at www.chemed.com
by clicking on Investor Relations Home.
A taped replay of the conference call will be available
beginning approximately 24 hours after the call's conclusion. It
can be accessed by dialing (888) 286-8010 for U.S. and Canadian
callers and (617) 801-6888 for international callers and will be
available for one week following the live call. The replay passcode
is 91024524. An archived webcast will also be available at
www.chemed.com.
Chemed Corporation operates in the healthcare field through its
VITAS Healthcare Corporation subsidiary. VITAS provides daily
hospice services to approximately 12,000 patients with severe,
life-limiting illnesses. This type of care is focused on making the
terminally ill patient's final days as comfortable and pain-free as
possible.
Chemed operates in the residential and commercial plumbing and
drain cleaning industry under the brand name Roto-Rooter.
Roto-Rooter provides plumbing and drain service through
company-owned branches, independent contractors and franchisees in
the United States and Canada. Roto-Rooter also has licensed master
franchisees in Indonesia, Singapore, Japan, and the
Philippines.
This press release contains information about Chemed�s EBITDA,
Adjusted EBITDA and Adjusted Diluted EPS, which are not measures
derived in accordance with GAAP and which exclude components that
are important to understanding Chemed�s financial performance. In
reporting its operating results, Chemed provides EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS measures to help investors and
others evaluate the Company's operating results, compare its
operating performance with that of similar companies that have
different capital structures and evaluate its ability to meet its
future debt service, capital expenditures and working capital
requirements. Chemed's management similarly uses EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS to assist it in evaluating the
performance of the Company across fiscal periods and in assessing
how its performance compares to its peer companies. These measures
also help Chemed's management to estimate the resources required to
meet Chemed's future financial obligations and expenditures.
Chemed�s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should
not be considered in isolation or as a substitute for comparable
measures calculated and presented in accordance with GAAP. We
calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by
service revenue and sales. A reconciliation of Chemed�s net income
to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is
presented in the tables following the text of this press
release.
Forward-Looking
Statements
Certain statements contained in this press release and the
accompanying tables are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "believe," "expect," "hope," "anticipate," "plan" and
similar expressions identify forward-looking statements, which
speak only as of the date the statement was made. Chemed does not
undertake and specifically disclaims any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. These
statements are based on current expectations and assumptions and
involve various risks and uncertainties, which could cause Chemed's
actual results to differ from those expressed in such
forward-looking statements. These risks and uncertainties arise
from, among other things, possible changes in regulations governing
the hospice care or plumbing and drain cleaning industries;
periodic changes in reimbursement levels and procedures under
Medicare and Medicaid programs; difficulties predicting patient
length of stay and estimating potential Medicare reimbursement
obligations; challenges inherent in Chemed's growth strategy; the
current shortage of qualified nurses, other healthcare
professionals and licensed plumbing and drain cleaning technicians;
Chemed�s dependence on patient referral sources; and other factors
detailed under the caption "Description of Business by Segment" or
"Risk Factors" in Chemed�s most recent report on form 10-Q or 10-K
and its other filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on such
forward-looking statements and there are no assurances that the
matters contained in such statements will be achieved.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATED
STATEMENT OF INCOME (in thousands, except per share
data)(unaudited) � � � � � � � � Three Months Ended March 31,
2009 2008 (bb) Service revenues and sales
$
294,938 � $ 285,268 � Cost of services provided and goods
sold (aa)
207,013 205,812 Selling, general and
administrative expenses (aa)
45,793 42,727 Depreciation
5,325 5,438 Amortization
1,536 1,450 Other operating
expenses (aa) �
545 � � - � Total costs and expenses �
260,212 � � 255,427 � Income from operations
34,726
29,841 Interest expense (aa)
(2,844 ) (3,109 ) Other
income--net (aa) �
(276 ) � (1,189 ) Income before
income taxes
31,606 25,543 Income taxes (aa) �
(12,267 ) � (9,683 ) Net Income
$
19,339 � $ 15,860 � �
Earnings Per Share (aa) Net
income
$ 0.86 � $ 0.66 � Average number of shares
outstanding �
22,394 � � 23,873 � �
Diluted Earnings Per
Share (aa) Net income
$ 0.85 � $ 0.65 � Average
number of shares outstanding �
22,647 � � 24,285 � � � � � �
� � � � (aa)
Included in the results of
operations are the following credits/(charges) which may not be
indicative of ongoing operations (in thousands, except per share
data):
� Three Months Ended March 31,
2009 2008 Cost of services
provided and goods sold
Unreserved prior-year's insurance
claim
$ - $ (597 ) Selling, general and administrative
expenses Stock option expense
(2,042 ) (1,391 )
Adjustments/(expenses) associated with OIG investigation
(13
) 15 Other operating expenses Expenses associated with
contested proxy solicitation
(545 ) - Interest
expense Additional interest expense resulting from the change in
accounting for the conversion feature of the convertible notes (bb)
(1,530 ) (1,512 ) Other income--net
Non-taxable income from certain
investments held in deferred compensation trusts
�
1,211 � � - � Pretax impact on earnings
(2,919
) (3,485 ) Income tax benefit on the above
1,517
1,292 Income tax impact of non-deductible net market losses on
investments held in deferred compensation trusts
(475
) - Income tax credit related to prior years �
- � �
322 � After-tax impact on earnings
$ (1,877 )
$ (1,871 ) � (bb)
Effective January 1, 2009, we
adopted the provisions of FASB Staff Position No. APB 14-1,
"Accounting for Convertible Debt Instruments That May Be Settled in
Cash upon Conversion (Including Partial Cash Settlement)."
Financial statements for 2008 and prior periods have been restated
for this change in accounting.
�
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEET (in thousands, except per share
data)(unaudited) � � � � � � � March 31,
2009 2008 (bb)
Assets Current assets Cash and cash equivalents
$
11,859 $ 29,704 Accounts receivable less allowances
107,364 87,004 Inventories
8,083 7,439 Current
deferred income taxes
16,692 14,996 Prepaid expenses and
other current assets �
9,046 � � 9,035 � Total current
assets
153,044 148,178 Investments of deferred compensation
plans held in trust
22,803 29,524 Properties and equipment,
at cost less accumulated depreciation
73,631 72,910
Identifiable intangible assets less accumulated amortization
60,748 64,168 Goodwill
450,000 438,656 Other assets �
13,999 � � 14,142 � Total Assets
$ 774,225 � $
767,578 � �
Liabilities Current liabilities Accounts payable
$ 48,883 $ 46,450 Current portion of long-term debt
10,070 10,166 Income taxes
13,872 10,100 Accrued
insurance
37,840 37,600 Accrued compensation
33,069
31,195 Other current liabilities �
14,715 � � 14,474 � Total
current liabilities
158,449 149,985 Deferred income taxes
22,239 22,991 Long-term debt
149,122 162,728 Deferred
compensation liabilities
22,691 29,653 Other liabilities �
4,581 � � 5,540 � Total Liabilities �
357,082 � �
370,897 �
Stockholders' Equity Capital stock
29,586
29,379 Paid-in capital
316,209 305,082 Retained earnings
355,723 290,412 Treasury stock, at cost
(286,427
) (230,594 ) Deferred compensation payable in Company stock
�
2,052 � � 2,402 � Total Stockholders' Equity �
417,143 � � 396,681 � Total Liabilities and Stockholders'
Equity
$ 774,225 � $ 767,578 � �
Book Value Per
Share $ 18.56 � $
16.72
� � � � � � � � � � � � � � (bb)
Effective January 1, 2009, we
adopted the provisions of FASB Staff Position No. APB 14-1,
"Accounting for Convertible Debt Instruments That May Be Settled in
Cash upon Conversion (Including Partial Cash Settlement)."
Financial statements for 2008 and prior periods have been restated
for this change in accounting.
�
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENT OF CASH FLOWS (in
thousands)(unaudited) � � � � � � � � � � � � Three Months Ended
March 31,
2009 2008 (bb)
Cash Flows from Operating
Activities Net income
$ 19,339 $ 15,860
Adjustments to reconcile net
income to net cash provided/(used) by operating activities:
Depreciation and amortization
6,861 6,888 Provision for
uncollectible accounts receivable
3,071 2,002 Stock option
expense
2,042 1,391 Provision for deferred income taxes
(1,529 ) (1,678 ) Amortization of discount on
convertible notes
1,612 1,612 Amortization of debt issuance
costs
154 154
Changes in operating assets and
liabilities, excluding amounts acquired in business
combinations:
Decrease in accounts receivable
(12,399 ) 12,112
Increase in inventories
(514 ) (843 ) Decrease in
prepaid expenses and other current assets
1,002 1,488
Decrease in accounts payable and other current liabilities
(7,900 ) (5,679 ) Increase in income taxes
13,056 6,677 Increase in other assets
(203 )
(293 ) Increase in other liabilities
486 532 Excess tax
benefit on share-based compensation
(145 ) (825 )
Other sources/(uses) �
168 � � 133 � Net cash provided by
operating activities �
25,101 � � 39,531 �
Cash Flows
from Investing Activities Capital expenditures
(3,376
) (3,891 ) Business combinations, net of cash acquired
(1,944 ) - Proceeds from sales of property and
equipment
1,360 19 Net proceeds/(uses) from the disposition
of discontinued operations
(121 ) 9,556 Other uses �
(31 ) � (122 ) Net cash provided/(used) by investing
activities �
(4,112 ) � 5,562 �
Cash Flows from
Financing Activities Purchases of treasury stock
(231
) (16,263 ) Repayment of long-term debt
(10,799
) (2,595 ) Dividends paid
(1,355 ) (1,449 )
Decrease in cash overdrafts payable
(342 ) (963 )
Excess tax benefit on share-based compensation
145 825 Other
sources �
(176 ) � 68 � Net cash used by financing
activities �
(12,758 ) � (20,377 )
Increase in
Cash and Cash Equivalents 8,231 24,716 Cash and cash
equivalents at beginning of year �
3,628 � � 4,988 � Cash
and cash equivalents at end of period �
11,859 � $ 29,704 �
� � � � � � � � � � � � � (bb) Effective January 1, 2009, we
adopted the provisions of FASB Staff Position No. APB 14-1,
"Accounting for Convertible Debt Instruments That May Be Settled in
Cash upon Conversion (Including Partial Cash Settlement)."
Financial statements for 2008 and prior periods have been restated
for this change in accounting. �
CHEMED CORPORATION AND
SUBSIDIARY COMPANIES CONSOLIDATING STATEMENT OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2009 AND 2008 (in
thousands)(unaudited) � � � � � � � � � �
Chemed
VITAS Roto-Rooter Corporate
Consolidated
�2009
� � Service revenues and sales $ 208,417 � $ 86,521 � $ - � $
294,938 � Cost of services provided and goods sold 159,631 47,382 -
207,013 Selling, general and administrative expenses (a) 17,546
24,375 3,872 45,793 Depreciation 3,219 2,054 52 5,325 Amortization
990 15 531 1,536
Other operating expenses (a)
� - � � - � � 545 � � 545 � Total costs and expenses � 181,386 � �
73,826 � � 5,000 � � 260,212 � Income/(loss) from operations 27,031
12,695 (5,000 ) 34,726 Interest expense (a) (39 ) (35 ) (2,770 )
(2,844 ) Intercompany interest income/(expense) 891 536 (1,427 ) -
Other income�net (a) � (3 ) �
116
� � (389 ) � (276 ) Income/(loss) before income taxes 27,880 13,312
(9,586 ) 31,606 Income taxes (a) � (10,597 ) � (5,036 ) � 3,366 � �
(12,267 ) Net income/(loss) $ 17,283 � $ 8,276 � $ (6,220 ) $
19,339 � �
�2008 (f)
� � Service revenues and sales $ 198,585 � $ 86,683 � $ - � $
285,268 � Cost of services provided and goods sold (b) 158,803
47,009 - 205,812 Selling, general and administrative expenses (b)
16,147 23,771 2,809 42,727 Depreciation 3,280 2,082 76 5,438
Amortization � 996 � � 13 � � 441 � � 1,450 � Total costs and
expenses � 179,226 � � 72,875 � � 3,326 � � 255,427 � Income/(loss)
from operations 19,359 13,808 (3,326 ) 29,841 Interest expense (b)
(51 ) (83 ) (2,975 ) (3,109 ) Intercompany interest
income/(expense) 1,365 1,042 (2,407 ) - Other income�net � 23 � �
28 � � (1,240 ) � (1,189 ) Income/(loss) before income taxes 20,696
14,795 (9,948 ) 25,543 Income taxes (b) � (7,398 ) � (5,700 ) �
3,415 � � (9,683 ) Net income/(loss) $ 13,298 � $ 9,095 � $ (6,533
) $ 15,860 � �
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARY OF EBITDA FOR THE THREE MONTHS
ENDED MARCH 31, 2009 AND 2008 (in thousands)(unaudited)
� � � � � � � � �
Chemed VITAS Roto-Rooter
Corporate Consolidated
�2009
� � � � � Net income/(loss) $ 17,283 $ 8,276 $ (6,220 ) $ 19,339
Add/(deduct): Interest expense 39 35 2,770 2,844 Income taxes
10,597 5,036 (3,366 ) 12,267 Depreciation 3,219 2,054 52 5,325
Amortization � 990 � � 15 � � 531 � � 1,536 � EBITDA 32,128 15,416
(6,233 ) 41,311 Add/(deduct): Non-taxable income from certain
investments held in deferred compensation trusts - - (1,211 )
(1,211 )
Expenses associated with contested
proxy solicitation
- - 545 545 Legal expenses of OIG investigation 13 - - 13 Stock
option expense - - 2,042 2,042 Advertising cost adjustment (c) -
(394 ) - (394 ) Interest income (48 ) (19 ) (15 ) (82 )
Intercompany interest income/(expense) � (891 ) � (536 ) � 1,427 �
� - � Adjusted EBITDA $ 31,202 � $ 14,467 � $ (3,445 ) $ 42,224 � �
2008 (f) � � � � � Net income/(loss) $ 13,298 $ 9,095 $ (6,533 ) $
15,860 Add/(deduct): Interest expense 51 83 2,975 3,109 Income
taxes 7,398 5,700 (3,415 ) 9,683 Depreciation 3,280 2,082 76 5,438
Amortization � 996 � � 13 � � 441 � � 1,450 � EBITDA 25,023 16,973
(6,456 ) 35,540 Add/(deduct): Unreserved insurance claim - 597 -
597 Legal expenses of OIG investigation (15 ) - - (15 ) Stock
option expense - - 1,391 1,391 Advertising cost adjustment (c) -
(570 ) - (570 ) Interest income (38 ) (18 ) (281 ) (337 )
Intercompany interest income/(expense) � (1,365 ) � (1,042 ) �
2,407 � � - � Adjusted EBITDA $ 23,605 � $ 15,940 � $ (2,939 ) $
36,606 � � The "Footnotes to Financial Statements" are integral
parts of this financial information. �
CHEMED CORPORATION AND
SUBSIDIARY COMPANIES RECONCILIATION OF ADJUSTED NET
INCOME FOR THE THREE MONTHS ENDED MARCH 31, 2009 AND
2008 (in thousands, except per share data)(unaudited) �
� � � � � �
2009
2008 (f) Net income as reported
$
19,339
$ 15,860 � Add/(deduct):
After-tax expenses associated with
contested proxy solicitation
345
- After-tax cost of legal expenses/(adjustments) of OIG
investigation
8
(9 ) After-tax stock option expense
1,292
884
After-tax additional interest
expense resulting from the change in accounting for the conversion
feature of the convertible notes
968
960
After-tax impact of non-deductible
losses and non-taxable gains on investments held in deferred
compensation trusts
(736
)
- Income tax credit related to prior years
-
(322 ) After-tax unreserved insurance cost �
-
� � 358 � � Adjusted net income
$
21,216
� $ 17,731 � � � Earnings Per Share As Reported Net income
$
0.86
� $ 0.66 � Average number of shares outstanding �
22,394
� � 23,873 � Diluted Earnings Per Share As Reported Net income
$
0.85
� $ 0.65 � Average number of shares outstanding �
22,647
� � 24,285 � � � Adjusted Earnings Per Share Net income
$
0.95
� $ 0.74 � Average number of shares outstanding �
22,394
� � 23,873 � Adjusted Diluted Earnings Per Share Net income
$
0.94
� $ 0.73 � Average number of shares outstanding �
22,647
� � 24,285 � � The "Footnotes to Financial Statements" are integral
parts of this financial information.
CHEMED CORPORATION AND
SUBSIDIARY COMPANIES OPERATING STATISTICS FOR VITAS
SEGMENT FOR THE THREE MONTHS ENDED MARCH 31, 2009 AND
2008 (unaudited) � � � � � � � � OPERATING STATISTICS
2009 2008 Net revenue ($000) (d) Homecare
$
147,075 $ 141,617 Inpatient
25,082 25,971 Continuous
care �
34,580 � � 30,997 Total before Medicare Cap allowance
and 2008 BNAF
$ 206,737 $ 198,585 Estimated BNAF
Accrual Q4 2008
1,950 - Medicare Cap allowance �
(270
) � - Total
$ 208,417 � $ 198,585
Net revenue as a percent of total
before Medicare Cap allowance
Homecare
71.1 % 71.3 % Inpatient
12.2 13.1
Continuous care �
16.7 � � 15.6 Total before Medicare Cap
allowance and 2008 BNAF
100.0 100.0 Estimated BNAF Accrual
Q4 2008
0.9 - Medicare Cap allowance �
(0.1 )
� - Total �
100.8 �
% � 100.0 % Average daily census
("ADC") (days) Homecare
7,477 7,154 Nursing home �
3,263 � � 3,548 Routine homecare
10,740 10,702
Inpatient
421 453 Continuous care �
567 � � 536 Total
�
11,728 � � 11,691 � Total Admissions
14,168 15,212
Total Discharges
13,865 14,992 Average length of stay (days)
76.6 71.5 Median length of stay (days)
13.0 13.0 ADC
by major diagnosis Neurological
32.5 % 32.5 % Cancer
19.6 20.0 Cardio
12.3 13.0 Respiratory
6.7 6.9
Other �
28.9 � � 27.6 Total �
100.0 �
% �
100.0 % Admissions by major diagnosis Neurological
18.6
% 19.0 % Cancer
35.9 33.4 Cardio
11.1 11.9
Respiratory
7.6 8.5 Other �
26.8 � � 27.2 Total �
100.0 �
% � 100.0 % Direct patient care margins (e)
Routine homecare
51.5 % 49.5 % Inpatient
17.4
19.3 Continuous care
19.1 16.5 Homecare margin drivers
(dollars per patient day) Labor costs
$ 52.82 $ 52.26
Drug costs
7.65 7.49 Home medical equipment
6.68 6.17
Medical supplies
2.27 2.57 Inpatient margin drivers (dollars
per patient day) Labor costs
$ 271.75 $ 266.18
Continuous care margin drivers (dollars per patient day) Labor
costs
$ 521.30 $ 509.62 Bad debt expense as a percent
of revenues
1.1 % 0.9 % Accounts receivable -- days
of revenue outstanding
68.4 45.5 � The "Footnotes to
Financial Statements" are integral parts of this financial
information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS FOR THE THREE MONTHS
ENDED MARCH 31, 2009 AND 2008 (unaudited) � � � � � � � � � � �
� (a)
Included in the results of
operations for the three months ended March 31, 2009, are the
following significant credits/(charges) which may not be indicative
of ongoing operations (in thousands):
�
VITAS �
Corporate Consolidated Selling,
general and administrative expenses Stock option expense
$ -
$ (2,042 )
$ (2,042 ) Legal expenses of OIG
investigation (13 ) - (13 ) Other operating expense Expenses
associated with contested proxy solicitation
-
(545 ) (545 ) Interest expense Additional interest expense
resulting from the change in accounting for the conversion feature
of the convertible notes
- (1,530 ) (1,530 ) Other
income-net Non-taxable income from certain investments held in
deferred compensation trusts � - � � 1,211 � � 1,211 � Pretax
impact on earnings (13 ) (2,906 ) (2,919 ) Income tax
benefit/(charge) on the above 5 1,512 1,517
Income tax impact of
non-deductible net market losses on investments held in deferred
compensation trusts
� - � � (475 ) � (475 ) After-tax impact on earnings $ (8 ) $
(1,869 ) $ (1,877 ) � (b)
Included in the results of
operations for the three months ended March 31, 2008, are the
following significant credits/(charges) which may not be indicative
of ongoing operations (in thousands):
�
VITAS �
Roto-Rooter Corporate (f)
Consolidated Cost of services provided and goods sold
Unreserved prior-year's insurance
claim
$ - $ (597 ) $ - $ (597 ) Selling, general and
administrative expenses Stock option expense
- - (1,391 )
(1,391 ) Legal expenses of OIG investigation 15 - - 15 Interest
expense Additional interest expense resulting from the change in
accounting for the conversion feature of the convertible notes � -
� � - � � (1,512 ) � (1,512 ) Pretax impact on earnings 15 (597 )
(2,903 ) (3,485 ) Income tax benefit/(charge) on the above (6 ) 239
1,059 1,292 Income tax credit related to prior years � 322 � � - �
� - � � 322 � After-tax impact on earnings $ 331 � $ (358 ) $
(1,844 ) $ (1,871 ) � (c)
Under Generally Accepted
Accounting Principles ("GAAP"), the Roto-Rooter segment expenses
all advertising, including the cost of telephone directories,
immediately upon the initial release of the advertising. Telephone
directories are generally in circulation 12 months. If a directory
is in circulation for a time period greater or less than 12 months,
the publisher adjusts the directory billing for the change in
billing period. The timing of when a telephone directory is
published can and does fluctuate significantly on a quarterly
basis. This "direct expensing" results in significant fluctuations
in quarterly advertising expense. In the first quarters of 2009 and
2008, GAAP advertising expense for Roto-Rooter totaled $5,757,000
and $5,456,000, respectively. If the expense of the telephone
directories were spread over the periods they are in circulation,
advertising expense for the first quarters of 2009 and 2008 would
total $6,151,000 and $6,026,000, respectively.
� (d)
VITAS has 5 large (greater than
450 ADC), 17 medium (greater than 200 but less than 450 ADC) and 23
small (less than 200 ADC) hospice programs. There is one continuing
program as of March 31, 2009, with Medicare Cap cushion of less
than 10% for the 2008 measurement period. There are two continuing
programs as of March 31, 2009, with Medicare Cap cushion of less
than 10% for the 2009 measurement period, including one program
with a $505,000 liability recorded at March 31, 2009.
� (e) Amounts exclude indirect patient care and administrative
costs, as well as Medicare Cap billing limitation. � (f)
Effective January 1, 2009, we
adopted the provisions of FASB Staff Position No. APB 14-1,
"Accounting for Convertible Debt Instruments That May Be Settled in
Cash upon Conversion (Including Partial Cash Settlement)."
Financial statements for 2008 and prior periods have been restated
for this change in accounting.
Chemed (NYSE:CHE)
Historical Stock Chart
From May 2024 to Jun 2024
Chemed (NYSE:CHE)
Historical Stock Chart
From Jun 2023 to Jun 2024